Crescent Biopharma (FRA:C68) Cyclically Adjusted PB Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:C68 Crescent Biopharma Inc FRA:C68
18 GF Score
Price €13.80
! 1 Warning Sign
View Full Analysis

What is Crescent Biopharma Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Crescent Biopharma  (FRA:C68) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Crescent Biopharma Cyclically Adjusted PB Ratio Related Terms


Crescent Biopharma Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Crescent Biopharma's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crescent Biopharma Cyclically Adjusted PB Ratio Chart

Crescent Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 0.05

Crescent Biopharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.05 0.04 0.06 0.07

FRA:C68 vs SGMT, MDXG, PRME: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Crescent Biopharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Crescent Biopharma Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Crescent Biopharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Crescent Biopharma's Cyclically Adjusted PB Ratio falls into.


FRA:C68
18GF Score
Crescent Biopharma Inc FRA:C68
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Crescent Biopharma Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Crescent Biopharma's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Crescent Biopharma's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=5.019/333.9520*333.9520
=5.019

Current CPI (Jun. 2026) = 333.9520.

Crescent Biopharma Quarterly Data

Book Value per Share CPI Adj_Book
201609 161.086 241.428 222.820
201612 143.951 241.432 199.115
201703 124.970 243.801 171.181
201706 309.347 244.955 421.739
201709 280.509 246.819 379.535
201712 290.120 246.524 393.009
201803 455.521 249.554 609.576
201806 453.546 251.989 601.068
201809 435.287 252.439 575.842
201812 416.432 251.233 553.543
201903 397.637 254.202 522.386
201906 363.010 256.143 473.282
201909 353.453 256.759 459.716
201912 316.039 256.974 410.710
202003 310.510 258.115 401.741
202006 277.795 257.797 359.858
202009 246.522 260.280 316.300
202012 213.786 260.474 274.094
202103 206.564 264.877 260.432
202106 183.714 271.696 225.810
202109 161.043 274.310 196.058
202112 137.169 278.802 164.302
202203 118.177 287.504 137.269
202206 101.680 296.311 114.597
202209 93.692 296.808 105.417
202212 73.973 296.797 83.233
202303 89.086 301.836 98.565
202306 78.102 305.109 85.485
202309 68.301 307.789 74.107
202312 54.004 306.746 58.794
202403 41.534 312.332 44.409
202406 29.030 314.175 30.857
202409 15.808 315.301 16.743
202412 7.958 315.605 8.421
202503 4.842 319.799 5.056
202506 8.294 322.561 8.587
202509 6.900 324.800 7.094
202512 6.149 324.054 6.337
202603 5.661 330.213 5.725
202606 5.019 333.952 5.019

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Crescent Biopharma Business Description

Other Exchanges CBIO:USA
Address 300 Fifth Avenue, Waltham, MA, USA, 02451
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
18GF Score

Get the complete analysis for FRA:C68

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.80
Price